Sandoz Strikes $195m Deal On US Price-Fixing
Admits Role In Antitrust Conspiracies As Part Of US Investigation
Executive Summary
Sandoz has agreed to pay a $195m criminal penalty, the largest for a US antitrust case, as part of a deferred prosecution agreement with the US Department of Justice to resolve antitrust allegations as part of the country’s ongoing investigation into generic price-fixing.
You may also be interested in...
Teva Pays Out $225m, Must Divest Pravastatin To Settle Criminal Price-Fixing Charges In US
Settlement with the US Department of Justice over criminal price-fixing charges includes donating $50m worth of medicines. Meanwhile, Glenmark has also struck a $30m settlement with the DoJ.
Teva Pays Out $225m To Settle Criminal Price-Fixing Charges In US
Teva has agreed to pay a $225m fine, as well as donating $50m worth of medicines and divesting a product from its portfolio, as part of a settlement with the US Department of Justice over criminal price-fixing charges. Meanwhile, Glenmark has also struck a $30m settlement with the DoJ.
Induced Infringement And Price Fixing Among Legal Headlines In 2021
In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.